[ad_1]
Synopsis
Granules has not only had a stellar stock performance but also delivered robust earnings growth. While focusing on its core business, which has high-volume and low-value products, the company has been expanding the product basket to include higher-margin products for the US. However, navigating the challenging business environment for generic drugs in the US could be difficult.
The pandemic has put the pharmaceutical sector under the spotlight, with a special focus on companies manufacturing active pharmaceutical ingredients (APIs), or raw materials to make finished products. While the pharma stocks have surged in the past six months with the Nifty Pharma Index rising over 80% from its low in March, API-focused companies such as Aarti Drugs, Laurus Labs, and Granules India have significantly outperformed the index.
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Why ?
-
Sharp Insight-rich, Indepth stories across 20+ sectors
-
Access the exclusive Economic Times stories, Editorial and Expert opinion
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link